A Study of BAX 888 in Male Adults With Severe Hemophilia A
Status:
Active, not recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
The main aim of this study is to check if there are side effects from BAX 888 and to
determine the dose of BAX 888 for treating severe hemophilia A in male adults.
Participants will receive one infusion with BAX 888 at the hemophilia treatment center.
During the study, participants will visit their study clinic multiple times.